Pulmonary anthrax
ICD-10 A22.1 · ICD-11 1B97/CA40.0

Treatment of Systemic Pulmonary Anthrax (Inhalation) in Children Aged 1 Month to Under 18 Years

Clinical Scenario

This protocol addresses pediatric patients aged 1 month to less than 18 years presenting with systemic anthrax from inhalation (pulmonary) exposure, with or without concurrent meningitis.

Treatment Approach

Empiric management in this age group involves a structured combination regimen — multiple antimicrobial agents paired with antitoxin as adjunctive therapy. The full drug selection criteria, class combinations, and transition guidance are available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

Empiric treatment regimens for children aged >1 month to <18 years with systemic anthrax with or without meningitis (Table 14) are summarized as follows:

Antimicrobial drugs: Choose two bactericidal drugs from different antimicrobial drug classes plus a PSI or an RNAI.

Antitoxin: Choose a single antitoxin as adjunctive therapy.

View source ↗